Integra LifeSciences Holdings C (IART) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.56
- Surprise
- —
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Integra Lifesciences Sees Q4 Adj EPS $0.61-$0.71 vs $0.76 Est; Sees Sales $413.000M-$433.000M vs $436.772M Est — benzinga, 2026-10-21
Where TrendMatrix's rating stands now
TrendMatrix currently rates IART Sell at 5.2/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate.
What argues against it
- Concentration risk — Product: CSS segment (70.0%)
- Risk below floor (2.3 < 2.5)
- Momentum score 4.2/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.33
- Price target
- $15.66
- Stop
- $12.40
- Upside to target
- +17.5%
- Reward-to-risk
- 1.4:1
Model outputs from TrendMatrix’s engine as of 2026-10-21 — shown for context, not personalized investment advice.
IART at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.04B
- P/E (fwd)
- 5.3
- 52-week range
- $8.70–$20.49
- Off 52-week high
- 34.9%
- RSI (14)
- 30
- Volume vs avg
- 1.20×
- Score today
- 5.2/10